Citi analyst Patrick Donnelly raised the firm’s price target on 10x Genomics to $75 from $65 and keeps a Buy rating on the shares post the Q2 report. Growth in the quarter was primarily driven by the healthy Xenium ramp and strong demand in Chromium consumables, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TXG:
- 10x Genomics raises 2023 revenue view to $600M-$630M from $590M-$610M
- 10x Genomics reports Q2 EPS (53c), consensus (40c)
- 10x Genomics Reports Second Quarter 2023 Financial Results
- Court permits NanoString counterclaim in 10x Genomics, Harvard litigation
- 10x Genomics assumed with an Overweight at JPMorgan